Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

AstraZeneca launches new FluMist® Quadrivalent flu vaccine for this flu season Français


News provided by

AstraZeneca Canada Inc.

Oct 26, 2015, 07:00 ET

Share this article

Share toX

Share this article

Share toX

The only intranasal flu vaccine for children two to 17 now provides broader protection1

MISSISSAUGA, ON, Oct. 26, 2015 /CNW/ - AstraZeneca Canada Inc. announced today the approval and availability of FluMist® Quadrivalent (FluMist), the only needle-free flu vaccine available in Canada that protects against two A strains of the flu, and for the first time, two B strains.2 FluMist has been shown to be 48 per cent more effective in children ages two to 17 than the traditional flu shot across all strains.3

FluMist addresses the growing issue of mismatched influenza strains. By adding a second B virus to the traditional trivalent vaccine, the likelihood of matching the major circulating B strain increases.4 In fact, Canada's National Advisory Committee on Immunization (NACI) recommends the use of a quadrivalent flu vaccine for the 2015-2016 flu season.5

"Last winter was particularly bad for the flu, and one reason was the poor match between the influenza vaccine available and the flu strains circulating in Canada," said Dr. Vivien Brown, a family physician and board member of Immunize Canada. "With the introduction of quadrivalent vaccines, such as FluMist, Canadians are more likely to be protected against this season's major circulating flu."

FluMist, a Live Attenuated Influenza Vaccine (LAIV), is administered through the nose, where the flu virus typically enters the body.6 This method closely mimics natural infection which contributes to its superior efficacy when compared to the traditional flu shot.7 NACI also recommends a LAIV vaccine like FluMist for children aged two to 17 compared to a traditional flu shot.8 FluMist is available through nearly all provincial and territorial immunization programs.

"FluMist gives parents reassurance that their children are protected against influenza with a safe and effective vaccine, without having to experience the discomfort or concerns that may come with the traditional injectable vaccine," said Dr. Brown.

Each flu season, 3.5 to 7 million Canadians (10 to 20 per cent of the population) will be infected with the flu,9 and more than 12,000 Canadians are expected to visit the hospital because of the flu and related illnesses.10 By vaccinating each flu season, Canadians who cannot receive a flu vaccine including infants, seniors and those with compromised or fragile immune systems may also be protected through herd immunity. Herd immunity is important especially in schools and among children, in senior or long-term care facilities and in those aged 65 and older. 11,12

To help protect against seasonal influenza, Canadians can receive FluMist this flu season at their doctor's office and select pharmacies.

For more information about FluMist, please visit flumistcanada.ca. Canadians can also find out if pharmacists in their province are able to administer the flu vaccine by visiting the 'Pharmacist's Role in Flu Vaccination' page on the Canadian Pharmacist's Association website at www.pharmacists.ca.

FluMist is available without a prescription across all Canadian provinces and territories with the exception of Quebec where a prescription is needed.

FluMist® is a registered trademark of MedImmune licensed to AstraZeneca.

About FluMist® Quadrivalent
When compared with placebo, efficacy of two doses of a LAIV administered to children who have never been vaccinated was 83 per cent against similar strains.13

The following provinces and territories include FluMist as a part of their vaccination programs: Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Northwest Territories, Ontario, Prince Edward Island, Quebec, Saskatchewan and Yukon. Canadians are encouraged to visit their respective provincial or territorial vaccination program websites to find out if they are eligible to receive FluMist.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca's Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at www.astrazeneca.ca.

B-Roll footage for this product is available at: https://edelmanftp.box.com/FluMist-broll-EN

___________________________________
1
Public Health Agency of Canada. Statement on Seasonal Influenza Vaccine for 2015-2016- Public Health Agency of Canada. 2015. Available at: http://www.phac-aspc.gc.ca/naci-ccni/flu-2015-grippe-eng.php.  Accessed May 4, 2015.
2 FluMist® Quadrivalent Product Monograph. May 8. 2015.
3 Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine. 2012;30(5):886-92.
4 Public Health Agency of Canada. Statement on Seasonal Influenza Vaccine for 2015-2016- Public Health Agency of Canada. 2015. Available at: http://www.phac-aspc.gc.ca/naci-ccni/flu-2015-grippe-eng.php. Accessed May 4, 2015.
5 Ibid.
6 FluMist® Quadrivalent Product Monograph. May 8. 2015.
7  Public Health Agency of Canada. Canada Communicable Disease Report CCDR. Revised Wording to the National Advisory Committee on Immunization (NACI) Recommendation for Live Attenuated Influenza Vaccine (LAIV) in Healthy Children and Adolescents 2-17 Years of Age. Nov. 14, 2013. Available at www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-4/rev-eng.php Accessed May 1, 2015
8 Public Health Agency of Canada. Statement on Seasonal Influenza Vaccine for 2015-2016- Public Health Agency of Canada. 2015. Available at: http://www.phac-aspc.gc.ca/naci-ccni/flu-2015-grippe-eng.php. Accessed May 4, 2015.
9 Ibid.
10 Ibid.
11 Barclay VC, Smieszek T, He J, Cao G, Rainey JJ, et al. Positive Network Assortativity of Influenza Vaccination at a High School: Implications for Outbreak Risk and Herd Immunity. 2014. PLoS ONE 9(2): e87042.
12 Government of Canada - Healthy Canadians. Flu – Risks. Available at:  http://healthycanadians.gc.ca/diseases-conditions-maladies-affections/disease-maladie/flu-grippe/risks-risques-eng.php Accessed June 15, 2015  
13 Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine. 2012;30(5):886-92.

SOURCE AstraZeneca Canada Inc.

Image with caption: "To help protect against seasonal influenza, Canadians can receive the FluMist® Quadrivalent vaccine through some public health programs for children (2-17), in doctor’s offices and at some pharmacies. Visit www.flumistcanada.ca for more information. (CNW Group/AstraZeneca Canada Inc.)". Image available at: http://photos.newswire.ca/images/download/20151026_C4527_PHOTO_EN_528211.jpg

Courtney McNamara, Edelman, Tel: (416) 849-3149, [email protected]; Stacey Brown, AstraZeneca Canada, Tel: (905) 803-5733, [email protected]

Modal title

Organization Profile

AstraZeneca Canada Inc.

    Also from this source

  • /C O R R E C T I O N from Source -- AstraZeneca Canada Inc., Plan International Canada, Eureka Fellowship/

  • Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)

  • AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.